JordanElizabethLakeMD

Infectious Disease • Houston, TX

Associate Professor, Medicine, University of Texas Health Science Center at Houston

Join to view full profile

Dr. Lake is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lake's full profile

Already have an account?

Office
2015 Thomas St
Houston, TX 77009
Phone+1 713-500-6759

Fax+1 832-487-2011

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 2007 - 2011
Baylor College of MedicineResidency, Internal Medicine, 2004 - 2007
Baylor College of MedicineClass of 2004

Certifications & Licensure

CA State Medical License 2007 - Present
TX State Medical License 2018 - 2025
American Board of Internal Medicine Infectious Disease

Clinical Trials

HIV and Fat Accumulation Start of enrollment: 2010 May 01
Completed
Phase 2
Vitamin D in HIV-Infected Patients on HAART Start of enrollment: 2010 Oct 01
Completed
Not Applicable
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease Start of enrollment: 2012 Aug 01
Completed
Phase 2
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Effects of Vitamin D Insufficiency in Man Start of enrollment: 2010 Aug 01
Completed
Not Applicable
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Start of enrollment: 2014 Jan 01
Completed
Phase 2
A Pilot Study to Examine Efficacy of Peer Mentoring in Promoting Medication Adherence Among People Living With HIV/AIDS Start of enrollment: 2013 Sep 01
Unknown status
Not Applicable
(mo)BETTA Trial in Transwomen for Optimization of ART Start of enrollment: 2018 Jun 06
Terminated
Phase 4
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) Start of enrollment: 2021 Feb 19
COMPLETED
PHASE2
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) Start of enrollment: 2020 Apr 24
Completed
Phase 3
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) Start of enrollment: 2020 Apr 15
Active, not recruiting
Phase 2
Ramipril for the Treatment of COVID-19 Start of enrollment: 2020 May 11
Completed
Phase 2
Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance Start of enrollment: 2020 Oct 22
Completed
Join now to see all

Publications & Presentations

PubMed

1 citations
Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex.
Cecile D Lahiri, C Christina Mehta, Qian Yang, Tsungirirai Maramba, Joffi Musonge-Effoe
Clinical Infectious Diseases. 2025-03-17
4 citations
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
Grace L Ditzenberger, Jordan E Lake, Douglas W Kitch, Amy Kantor, Raja Muthupillai
Clinical Infectious Diseases. 2025-02-24
Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA.
Amaya Perez-Brumer, Rose Schmidt, Rebecca Kennedy, Jordan E Lake, Yolanda R Villarreal
Addiction Science & Clinical Practice. 2024-12-18

Journal Articles

To T or Not to T: Differences in Testosterone Use and Discontinuation by HIV Serostatus Among Men Who Have Sex with Men*
T T Brown, J E Lake, W S Post, A Dobs, HIV Medicine

Grant Support

Metabolic impact of FGF-21 in adipose tissue and liver of PLWHUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2020–2025